Zsa Zsa Weerts

Chapter 8 204 References 1. Lovell R, Ford A. Global prevalence of and risk factors for irritable bowel syndrome: a meta- analysis. Clin Gastroenterol Hepatol 2012;10:712-721 e714. 2. Canavan C, West J, Card T. Review article: the economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther 2014;40:1023-1034. 3. Cash B. Economic impact of irritable bowel syndrome: what does the future hold? Am J Manag Care 2005;11:S4-6. 4. Cash B, Sullivan S, Barghout V. Total costs of IBS: employer and managed care perspective. Am J Managed Care 2005;11:S7-16. 5. Inadomi J, Fennerty M, Bjorkman D. Systematic review: the economic impact of irritable bowel syndrome. Aliment Pharmacol Ther 2003;18:671-682. 6. Corsetti M, Whorwell P. The global impact of IBS: time to think about IBS-specific models of care? Therap Adv Gastroenterol 2017;10:727- 736. 7. Ballou S, Keefer L. The impact of irritable bowel syndrome on daily functioning: Characterizing and understanding daily consequences of IBS. Neurogastroenterol Motil 2017;29. 8. Lea R, Whorwell P. Quality of life in irritable bowel syndrome. Pharmacoeconomics 2001;19:643-653. 9. Weerts Z, Masclee A, Witteman B, et al. Efficacy and Safety of Peppermint Oil in a Randomized Double-blind Trial of Patients With Irritable Bowel Syndrome. Gastroenterology 2019;DOI 10.1053/j.gastro.2019.08.026. 10. Black CJ, Yuan Y, Selinger CP, et al. Efficacy of soluble fibre, antispasmodic drugs, and gut- brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol 2020;5:117-131. 11. Mearin F, Lacy BE, Chang L, et al. Bowel disorders. Gastroenterology . 2016;150(6): 1393-1407 12. Weerts Z, Keszthelyi D, Vork L, et al. A Novel Ileocolonic Release Peppermint Oil Capsule for Treatment of Irritable Bowel Syndrome: A Phase I Study in Healthy Volunteers. Adv Ther 2018;DOI 10.1007/s12325-018-0802-1. 13. Kanters T, Bouwmans C, van der Linden N, et al. Update of the Dutch manual for costing studies in health care. PloS One 2017;12:e0187477. 14. Zorginstituut-Nederland; Hakkaart-van Roijen L, van der Linden N, et al. Costing manual: Methodology of costing research and reference prices for economic evaluations in healthcare. 2015. 15. Bouwmans C, Krol M, Brouwer W, et al. IMTA Productivity Cost Questionnaire (IPCQ). Value Health 2014;17:A550. 16. Bushnell D, Martin M, Ricci J. Performance of the EQ-5D in patients with irritable bowel syndrome. Value Health 2006;9:90-97. 17. Versteegh M, Vermeulen K, Evers S. Dutch Tariff for the Five-Level Version of EQ-5D. Value Health 2016;19:343-352. 18. Drossman D, Patrick D, Whitehead W, et al. Further validation of the IBS-QOL: a disease- specific quality-of-life questionnaire. Am J Gastroenterol 2000;95:999. 19. Faria R, Gomes M, Epstein D, et al. A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials. Pharmacoeconomics 2014;32:1157-1170. 20. van Asselt A, van Mastrigt G, Dirksen C, et al. How to deal with cost differences at baseline. Pharmacoeconomics 2009;27(6):519-28. 21. Polsky D, Glick HA, Willke R, et al. Confidence intervals for cost-effectiveness ratios: a comparison of four methods. Health Econ 1997;6:243-252. 22. Campbell MK, Torgerson DJ. Bootstrapping: estimating confidence intervals for cost- effectiveness ratios. QJM 1999;92:177-182. 23. Briggs A, Wonderling D, Mooney C. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997;6:327- 340. 24. Saase L, Zwaap J, Knies S, et. al. Cost- effectiveness in practice. Zorginstituut Nederland. 2015. 25. Stamuli E, Bloor K, MacPherson H, et al. Cost- effectiveness of acupuncture for irritable bowel syndrome: findings from an economic